Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259441 | 0.87 | OPRM1 (0.42) | OPRM1OPRD1OPRK1OPRL1GRIN2D | |
| SCHEMBL23077819 | 0.82 | CRHBP (0.34) | — | |
| SCHEMBL8260611 | 0.71 | GRIN2D (0.35) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL8259117 | 0.71 | S1PR2 (0.34) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL4546610 | 0.70 | GRIN2B (0.31) | GRIN2BGRIN2C | |
| SCHEMBL10033713 | 0.70 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1GRIN2D | |
| SCHEMBL680662 | 0.69 | GRIN2D (0.36) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL19507323 | 0.68 | GRIN2D (0.31) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL16117658 | 0.67 | GRIN2D (0.39) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL20381548 | 0.67 | GRIN2D (0.39) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | OPRM1 6/4885OPRD1 9/4885OPRK1 5/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | OPRM1 7/4885OPRD1 24/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.